	Frais De Vente Et D'Administration		Date
AbbVie	USD 3.89B	325M	2025-12
Agenus	USD 23.6M	448K	2025-09
Amgen	USD 1.94B	237M	2025-12
AstraZeneca	USD 148M	4.86B	2025-09
Bristol-Myers Squibb	USD 2.18B	392M	2025-12
Celldex Therapeutics	USD 6.63M	546K	2025-09
CSL	USD 727M	453M	2025-06
Dynavax Technologies	USD 40.09M	1.45M	2025-09
Eli Lilly	USD 3.13B	391.3M	2025-12
Gilead Sciences	USD 1.35B	6M	2025-09
GlaxoSmithKline	GBP 2.68B	518M	2025-12
Glaxosmithkline	GBP 2.91B	817.89M	2025-09
Incyte	USD 390.41M	61.33M	2025-12
Intrexon	USD 10.31M	41K	2024-06
J&J	USD 6.75B	831M	2025-12
Jiangsu Hengrui	CNY 3.23B	111.82M	2025-09
Karyopharm Therapeutics	USD 27.19M	442K	2024-12
MacroGenics	USD 9.9M	600K	2025-09
Merck	EUR 1.46B	16M	2025-09
Merck	USD 2.85B	215M	2025-12
Novartis	USD 3.31B	134M	2025-09
Novavax	USD 66.95M	34.05M	2024-09
Pfizer	USD 4.08B	894M	2025-12
Regeneron Pharmaceuticals	USD 775M	117.2M	2025-12
Rigel Pharmaceuticals	USD 27.04M	1M	2024-09
Sangamo BioSciences	USD 9.64M	1.83M	2024-06
Veracyte	USD 51.73M	5.91M	2025-09

Agenus Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.